Obermatt
See Similar Stocks →

Fulgent Genetics

NMQ:FLGT · US3596641098
Health Care Providers & ServicesMedium

360

4
EV / EBIT100
Price / Owner Earnings74
Owner Earnings Yield1
Dividend Yield1
Price/Sales93
Price/Book67
Return on Capital14
Cash Return on Capital26
Return on Equity32
EBIT Margin6
Gross Profitability9
Accruals57
Owner Earnings Margin14
Sales growth49
Profit Growth77
Long-Term EPS Growth1
Reinvestment84
Price momentum20
Debt load84
Refinancing99
Debt Payback1
Liquidity12
Analyst ratings1
Opinion Changes2
Price Target Upside6
Market mood1
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Fulgent Genetics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2016
Employees382
Websitefulgentgenetics.com
ISINUS3596641098
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsHematologyUrologyOncologyGeneticsBiotechnologyHealth Care

Description

Fulgent Genetics, Inc., together with its subsidiaries, operates as a technology-based company with a well-established laboratory services business and a therapeutic development business. The company’s laboratory services business includes technical…

Analysis

Weak and unloved

Fulgent Genetics, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
59
2023202420252026

All-time high

87

Jan 2023

All-time low

28

Jan 2025

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
36
7
15
Price/Earnings
75
84
84
83
Price/Book
67
84
84
56
Dividend Yield
1
1
1
1
Value (overall)
67
54
39
52

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Fulgent Genetics with its peers
Nuvectis Pharma
NAQ:NVCT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
NeoGenomics
NAQ:NEO
31
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Tempus AI
NSQ:TEM
28
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Surrozen
NAQ:SRZN
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Quest Diagnostics
NYQ:DGX
35
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →